ArticlePloS one2025
Assessing the diagnostic accuracy of biochemical, anthropometric, and combined indices for metabolic syndrome prediction in a cohort from Qatar Biobank.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic syndrome (MetS) poses a substantial health risk, particularly in Qatar. This study aimed to compare the diagnostic accuracy of various indices for MetS identification in a well-characterized Qatari cohort from Qatar Biobank (QBB).
methodsThis cross-sectional study included 692 adults (≥18 years) from the QBB, categorized into MetS and healthy groups using the International Diabetes Federation (IDF) criteria. We compared the distributions of biochemical, anthropometric, and combined indices between groups. Logistic regression assessed associations with MetS, adjusting for demographics. Receiver Operating Characteristic (ROC) analysis evaluated discriminative performance and identified optimal thresholds. Robustness was tested using a 75/25 train-test split. Stratified analyses examined the influence of age, gender, and nationality.
resultsThe MetS prevalence was 19.1% among participants. Individuals with MetS displayed significantly higher levels of all indices compared to the healthy group. Triglycerides (adjusted odd ratio (AOR): 4.93), waist circumference (AOR: 3.87), and lipid accumulation product (LAP) (AOR: 14.91) showed the strongest associations within their respective categories. LAP achieved the highest discriminative performance (area under the curve (AUC): 0.896; 95% CI: 0.870-0.923), followed by the visceral adiposity index (VAI) (AUC: 0.877) and TyG × waist circumference (AUC: 0.872). LAP's optimal threshold was 37.1, with a sensitivity of 0.856 and a specificity of 0.789. Combined indices consistently outperformed individual measures. Discriminative accuracy was comparable across genders and nationalities but higher in individuals under 45 years.
conclusionCombined indices, particularly LAP, demonstrate superior discriminative ability for MetS in this Qatari cohort. Incorporating LAP into routine clinical practice could improve MetS detection and facilitate timely interventions. Further validation in larger, diverse populations is, however, warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.